The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Idiopathic Hypersomnia Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.
The global Idiopathic Hypersomnia Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Idiopathic Hypersomnia Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Idiopathic Hypersomnia Treatment market. Stimulant Medications, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Stimulant Wake-Promoting Medications segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Idiopathic Hypersomnia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Idiopathic Hypersomnia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Idiopathic Hypersomnia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Idiopathic Hypersomnia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Idiopathic Hypersomnia Treatment covered in this report include Takeda Pharmaceutical, Teva Pharmaceutical Industries, Jazz Pharmaceuticals, BIOPROJET, Avadel Pharmaceuticals, GlaxoSmithKline, Pfizer, Theranexus and Fisher and Paykel Healthcare, etc.
The global Idiopathic Hypersomnia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Jazz Pharmaceuticals
BIOPROJET
Avadel Pharmaceuticals
GlaxoSmithKline
Pfizer
Theranexus
Fisher and Paykel Healthcare
Drive DeVilbiss Healthcare
Merck
Global Idiopathic Hypersomnia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Idiopathic Hypersomnia Treatment market, Segment by Type:
Stimulant Medications
Non-Stimulant Wake-Promoting Medications
Sodium Oxybate
Global Idiopathic Hypersomnia Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Idiopathic Hypersomnia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Idiopathic hypersomnia (IH) is a rare sleep disorder marked by an over sleeping duration time during the day even after a longer sleeping hours of night sleep. People with idiopathic hypersomnia sleep normal or for long hours each night but still feel excessively sleepy during the day. Idiopathic hypersomnia is a type of hypersomnia and symptoms include chronic excessive daytime sleepiness (EDS), non-refreshing daytime napping, sleep drunkenness after nighttime sleep, naps, and others. Idiopathic hypersomnia is a nervous system disease, whose cause is not known. There is no single drug available that is approved by the U.S. FDA for this disease, but medicines such as dextroamphetamine that are approved for narcolepsy, one of the types of hypersomnia can be used for idiopathic hypersomnia off-label.
The global Idiopathic Hypersomnia Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Idiopathic Hypersomnia Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Idiopathic Hypersomnia Treatment market. Stimulant Medications, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Stimulant Wake-Promoting Medications segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Idiopathic Hypersomnia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Idiopathic Hypersomnia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Idiopathic Hypersomnia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Idiopathic Hypersomnia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Idiopathic Hypersomnia Treatment covered in this report include Takeda Pharmaceutical, Teva Pharmaceutical Industries, Jazz Pharmaceuticals, BIOPROJET, Avadel Pharmaceuticals, GlaxoSmithKline, Pfizer, Theranexus and Fisher and Paykel Healthcare, etc.
The global Idiopathic Hypersomnia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Jazz Pharmaceuticals
BIOPROJET
Avadel Pharmaceuticals
GlaxoSmithKline
Pfizer
Theranexus
Fisher and Paykel Healthcare
Drive DeVilbiss Healthcare
Merck
Global Idiopathic Hypersomnia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Idiopathic Hypersomnia Treatment market, Segment by Type:
Stimulant Medications
Non-Stimulant Wake-Promoting Medications
Sodium Oxybate
Global Idiopathic Hypersomnia Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Idiopathic Hypersomnia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Idiopathic Hypersomnia Treatment
1.1 Idiopathic Hypersomnia Treatment Market Overview
1.1.1 Idiopathic Hypersomnia Treatment Product Scope
1.1.2 Idiopathic Hypersomnia Treatment Market Status and Outlook
1.2 Global Idiopathic Hypersomnia Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Idiopathic Hypersomnia Treatment Market Size by Region (2018-2029)
1.4 Global Idiopathic Hypersomnia Treatment Historic Market Size by Region (2018-2023)
1.5 Global Idiopathic Hypersomnia Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Idiopathic Hypersomnia Treatment Market Size (2018-2029)
1.6.1 North America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
1.6.2 Europe Idiopathic Hypersomnia Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size (2018-2029)
1.6.4 Latin America Idiopathic Hypersomnia Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size (2018-2029)
2 Idiopathic Hypersomnia Treatment Market by Type
2.1 Introduction
2.1.1 Stimulant Medications
2.1.2 Non-Stimulant Wake-Promoting Medications
2.1.3 Sodium Oxybate
2.2 Global Idiopathic Hypersomnia Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Idiopathic Hypersomnia Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Idiopathic Hypersomnia Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Idiopathic Hypersomnia Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Idiopathic Hypersomnia Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Idiopathic Hypersomnia Treatment Revenue Breakdown by Type (2018-2029)
3 Idiopathic Hypersomnia Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Idiopathic Hypersomnia Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Idiopathic Hypersomnia Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Idiopathic Hypersomnia Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Idiopathic Hypersomnia Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Idiopathic Hypersomnia Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Idiopathic Hypersomnia Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Idiopathic Hypersomnia Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Idiopathic Hypersomnia Treatment Revenue Breakdown by Application (2018-2029)
4 Idiopathic Hypersomnia Treatment Competition Analysis by Players
4.1 Global Idiopathic Hypersomnia Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Idiopathic Hypersomnia Treatment as of 2022)
4.3 Date of Key Players Enter into Idiopathic Hypersomnia Treatment Market
4.4 Global Top Players Idiopathic Hypersomnia Treatment Headquarters and Area Served
4.5 Key Players Idiopathic Hypersomnia Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Idiopathic Hypersomnia Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Takeda Pharmaceutical
5.1.1 Takeda Pharmaceutical Profile
5.1.2 Takeda Pharmaceutical Main Business
5.1.3 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.1.4 Takeda Pharmaceutical Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Takeda Pharmaceutical Recent Developments
5.2 Teva Pharmaceutical Industries
5.2.1 Teva Pharmaceutical Industries Profile
5.2.2 Teva Pharmaceutical Industries Main Business
5.2.3 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.2.4 Teva Pharmaceutical Industries Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Teva Pharmaceutical Industries Recent Developments
5.3 Jazz Pharmaceuticals
5.3.1 Jazz Pharmaceuticals Profile
5.3.2 Jazz Pharmaceuticals Main Business
5.3.3 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.3.4 Jazz Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 BIOPROJET Recent Developments
5.4 BIOPROJET
5.4.1 BIOPROJET Profile
5.4.2 BIOPROJET Main Business
5.4.3 BIOPROJET Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.4.4 BIOPROJET Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 BIOPROJET Recent Developments
5.5 Avadel Pharmaceuticals
5.5.1 Avadel Pharmaceuticals Profile
5.5.2 Avadel Pharmaceuticals Main Business
5.5.3 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.5.4 Avadel Pharmaceuticals Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Avadel Pharmaceuticals Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.6.4 GlaxoSmithKline Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.7.4 Pfizer Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Theranexus
5.8.1 Theranexus Profile
5.8.2 Theranexus Main Business
5.8.3 Theranexus Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.8.4 Theranexus Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Theranexus Recent Developments
5.9 Fisher and Paykel Healthcare
5.9.1 Fisher and Paykel Healthcare Profile
5.9.2 Fisher and Paykel Healthcare Main Business
5.9.3 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.9.4 Fisher and Paykel Healthcare Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Fisher and Paykel Healthcare Recent Developments
5.10 Drive DeVilbiss Healthcare
5.10.1 Drive DeVilbiss Healthcare Profile
5.10.2 Drive DeVilbiss Healthcare Main Business
5.10.3 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.10.4 Drive DeVilbiss Healthcare Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Drive DeVilbiss Healthcare Recent Developments
5.11 Merck
5.11.1 Merck Profile
5.11.2 Merck Main Business
5.11.3 Merck Idiopathic Hypersomnia Treatment Products, Services and Solutions
5.11.4 Merck Idiopathic Hypersomnia Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Merck Recent Developments
6 North America
6.1 North America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Idiopathic Hypersomnia Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Hypersomnia Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Idiopathic Hypersomnia Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Hypersomnia Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Idiopathic Hypersomnia Treatment Market Dynamics
11.1 Idiopathic Hypersomnia Treatment Industry Trends
11.2 Idiopathic Hypersomnia Treatment Market Drivers
11.3 Idiopathic Hypersomnia Treatment Market Challenges
11.4 Idiopathic Hypersomnia Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
